Parcion Private Wealth LLC Invests $475,000 in United Therapeutics Corporation $UTHR

Parcion Private Wealth LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 974 shares of the biotechnology company’s stock, valued at approximately $475,000.

Several other hedge funds have also added to or reduced their stakes in the company. Darwin Global Management Ltd. bought a new stake in United Therapeutics during the 3rd quarter worth about $317,617,000. Baillie Gifford & Co. acquired a new position in United Therapeutics during the 4th quarter valued at about $157,390,000. Balyasny Asset Management L.P. boosted its stake in shares of United Therapeutics by 863.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after purchasing an additional 136,883 shares during the last quarter. Sofinnova Investments Inc. bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $34,055,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $48,167,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $471.91, for a total value of $10,617,975.00. The SEC filing for this sale provides additional information. Insiders sold a total of 403,295 shares of company stock valued at $211,274,496 in the last three months. 10.30% of the stock is owned by company insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $580.51 on Friday. The firm’s 50 day simple moving average is $524.67 and its 200 day simple moving average is $488.35. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $607.89. The company has a market capitalization of $25.44 billion, a price-to-earnings ratio of 20.81, a P/E/G ratio of 1.65 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.19 earnings per share. Equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Wells Fargo & Company increased their price target on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.